Azitra, Inc.

Listed Company

AZTRCIK 0001701478NYSEEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

Net Income

$-10.96M

Total Assets

$5.03M

Equity

$3.80M

Shares Out

16.19M

Op. Cash Flow

$-11.20M

AZTR$0.14−38.56% · past yearDBEQ Basic

Daily closing prices

Business

Azitra, Inc. is an early-stage clinical biopharmaceutical company developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company's proprietary platform includes a microbial library of approximately 1,500 unique bacterial strains and AI/machine learning technology to screen for therapeutic characteristics. Three lead product candidates—ATR-12 for Netherton syndrome, ATR-04 for EGFRi-associated rash, and ATR-01 for ichthyosis vulgaris—are in clinical development targeting dermatologic diseases with limited treatment options. The company operates primarily in the United States and relies on third-party contract manufacturers for production and clinical trial support.

Summary from 10-K filed 2026-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Service revenue - related party	0	7,500	686,000	284,000
Total revenue	0	7,500	686,000	284,000
General and administrative	6	6	4	4
Research and development	5	5	4	6
Total operating expenses	11	11	8	10
Loss from operations	−11	−11	−7	−9
Interest income	70,209	122,553	1,577	4,818
Interest expense	−7,587	−12,160	−167,726	—
Change in fair value of warrants	381	4	34,930	—
Loss on issuance of common stock	0	−2	0	—
Other (expense) income	−43,389	15,014	−54,608	−25,351
Total other income	19,614	2	−4	−1
Loss before income taxes	−11	−9	−11	−11
Income tax expense	−8,319	−9,031	−17,308	—
Net loss attributable to common shareholders	−11	−9	−11	−11
Net loss per share, basic (in dollars per share)	−2.25	−15.7	−54.98	−12.74
Net loss per share, diluted (in dollars per share)	−2.25	−15.7	−54.98	−12.74
Weighted average common stock outstanding, basic (in shares)	5	571,162	229,866	1
Weighted average common stock outstanding, diluted (in shares)	5	571,162	229,866	1

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2025 2025-06-30	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash and cash equivalents	2	—	5	2	3
Accounts receivable	912	—	233	—	175,000
Tax credits receivable	140,383	—	101,663	118,383	69,666
Deferred offering costs	0	—	4,106	67,859	216,886
Prepaid expenses	809,949	—	567,569	448,257	160,133
Total current assets	3	—	5	3	4
Property and equipment, net	548,591	—	653,957	710,075	846,958
Financing lease right-of-use asset, net	9,041	—	24,522	40,002	—
Operating lease right-of-use asset, net	404,444	—	527,393	828,960	1
Intangible assets, net	316,673	—	246,420	210,881	219,567
Deferred patent costs	679,908	—	593,802	742,229	800,831
Deferred issuance costs	0	—	37,477	0	—
Other assets	47,402	—	46,941	47,760	—
Total assets	5	—	7	5	7
Accounts payable	399,356	—	490,255	897,272	784,687
Income tax payable	6,256	—	11,572	0	—
Current financing lease liability	10,111	—	16,066	14,600	—
Current operating lease liability	255,776	—	255,177	307,655	287,384
Insurance premium financing liability	198,983	—	0	—	—
Accrued expenses	197,484	—	602,787	383,668	993,961
Total current liabilities	1	—	1	2	2
Long-term financing lease liability	0	—	10,105	26,169	—
Long-term operating lease liability	156,190	—	274,161	537,523	840,896
Warrant liability	0	—	381	35,453	70,283
Total liabilities	1	—	2	2	10
Commitments and contingencies (Note 12)	—	—	—	—	—
Preferred stock; $0.0001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; 0 shares issued at December 31, 2025 and December 31, 2024	0	—	0	0	—
Common stock; $0.0001 par value, 200,000,000 and 100,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively, 10,740,697 and 1,145,038 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	1,074	—	114	40	104
Additional paid-in capital	72	—	63	52	1
Accumulated deficit	−69	—	−58	−49	−37
Total stockholders' equity	4	2	6	3	−36
Total liabilities and stockholders' equity	5	—	7	5	7

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Depreciation and amortization	138,069	131,188	129,653	125,885
Loss on lease modification	10,896	0	—	—
Amortization of right-of-use assets	315,075	317,047	295,896	280,092
Change in foreign currency rates on remeasurement of Canadian fixed assets	0	−14,198	0	—
Stock based compensation	62,744	245,053	151,505	184,465
Change in fair value of warrant liability	−381	−4	−34,830	−821
Loss on disposal of property and equipment	2,069	4,859	41,417	7,923
Impairment of intangible assets and deferred patent costs	0	442,793	351,360	—
Accounts receivable	−679	98,022	84,565	−21,953
Prepaid expenses	53,180	−119,312	−288,124	−49,844
Other assets	−461	819	−253	694
Tax credits receivable	−38,720	16,720	−48,717	—
Income tax payable/receivable	−5,316	18,408	6,886	−15,024
Accounts payable and accrued expenses	−500,318	−140,535	−68,684	420,752
Operating lease liability	−304,913	−315,840	−283,102	−268,509
Net cash used in operating activities	−11	−10	−7	−8
Purchases of property and equipment	−24,213	−8,569	−26,544	−33,101
Proceeds from sale of property and equipment	3,153	0	—	4,250
Deferred patent costs	−161,849	−370,677	−214,152	−180,802
Net cash used in investing activities	−182,909	−379,246	−318,259	−336,761
Payment of deferred offering/issuance costs	−286	−37,477	0	—
Principal payments on finance leases	−16,061	−14,598	−7,392	—
Proceeds from public offerings, net	2	13	6	—
Proceeds from private placement, net	1	0	—	—
Proceeds from equity line of credit, net	6	0	—	—
Repayment of insurance premium financing liability	−96,577	0	—	—
Proceeds from exercise of stock options	0	19,100	0	1,510
Net cash provided by financing activities	9	13	6	4
Net change in cash and cash equivalents	−2	3	−2	−5
Financed insurance premium exchanged for prepaid insurance	295,560	0	—	—
Purchases of fixed assets in accounts payable	0	45,999	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Azitra, Inc.'s CIK number?

Azitra, Inc.'s SEC CIK number is 0001701478 (1701478). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Azitra, Inc.'s SEC filings?

All of Azitra, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Azitra, Inc. last report earnings?

Azitra, Inc. (AZTR) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001701478-26-000029). This is Azitra, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Azitra, Inc.'s most recent earnings 8-K?

Azitra, Inc.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001701478-26-000029. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Azitra, Inc.'s latest earnings 8-K →
Look up any company's CIK number →